| Metric | Value (₹ Cr) | Q1 FY25 |
|---|---|---|
| Revenue | 338.74 | 19.3% |
| Total Income | 342.77 | 19.9% |
| Expenditure | 253.96 | 4.5% |
| PBT | 88.81 | 289.0% |
| Net Profit | 66.18 | 294.4% |
| OPM | 26.67% | 21.97pp |
| NPM | 19.31% | 13.44pp |
| EPS | 39.87 | 294.4% |
Procter & Gamble Health Reports 20% Sales Growth in Q1 2025
01 Aug 2025 · 1 Aug 2025, 02:14 pm
Summary
Procter & Gamble Health Limited announced its financial results for the First Quarter ended June 30, 2025. The company delivered a strong performance with sales of $333 crores, up 20% versus a year ago, and Profit After Tax (PAT) stood at = 66 crores, versus = 17 crores a year ago.
Key Highlights
- 1
Sales up 20% for the quarter ended June 30, 2025
- 2
Broad-based growth in domestic and exports business
- 3
Profit After Tax (PAT) stood at = 66 crores, versus = 17 crores a year ago
- 4
One-time impact of impairment in the base period
Management Comments
Mr. Milind Thatte
We are pleased with the continued momentum and strong start to the Financial Year 2025-26. These results are a reflection of our commitment towards addressing the evolving needs of our consumers and healthcare professionals, via superior brand building and go to market initiatives while improving supply chain capabilities.
Informational and educational content only. Not investment advice.